{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:13:25Z","timestamp":1791357205800,"version":"4.3.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T00:00:00Z","timestamp":1567036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s10194-019-1044-6","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T13:03:14Z","timestamp":1567083794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Robert E.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7428-4355","authenticated-orcid":false,"given":"Helen M.","family":"Hochstetler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen B.","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin Gautier","family":"Doty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal J.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,29]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S0025-6196(11)60561-2","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MF, Lipton RB (2009) Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc 84:422\u2013435","journal-title":"Mayo Clin Proc"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/JOM.0b013e31803b9510","volume":"49","author":"K Hawkins","year":"2007","unstructured":"Hawkins K, Wang S, Rupnow MF (2007) Indirect cost burden of migraine in the United States. J Occup Environ Med 49:368\u2013374","journal-title":"J Occup Environ Med"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211\u20131259","journal-title":"Lancet"},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P (2017) Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 357:j2099","journal-title":"BMJ"},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"e020498","DOI":"10.1136\/bmjopen-2017-020498","volume":"8","author":"AN Mahmoud","year":"2018","unstructured":"Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M et al (2018) Migraine and the risk of cardiovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects. BMJ Open 8:e020498","journal-title":"BMJ Open"},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"i2610","DOI":"10.1136\/bmj.i2610","volume":"353","author":"T Kurth","year":"2016","unstructured":"Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB et al (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610","journal-title":"BMJ"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jama.296.3.283","volume":"296","author":"T Kurth","year":"2006","unstructured":"Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283\u2013291","journal-title":"JAMA"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1526-4610.2007.00937.x","volume":"47","author":"C Becker","year":"2007","unstructured":"Becker C, Brobert GP, Almqvist PM, Johansson S, Jick SS, Meier CR (2007) Migraine and the risk of stroke, TIA, or death in the UK (CME). Headache 47:1374\u20131384","journal-title":"Headache"},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ene.12701","volume":"22","author":"S Sacco","year":"2015","unstructured":"Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F et al (2015) Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol 22:1001\u20131011","journal-title":"Eur J Neurol"},{"key":"1044_CR10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/0333102416642602","volume":"37","author":"KP Peng","year":"2017","unstructured":"Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ (2017) Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia 37:327\u2013335","journal-title":"Cephalalgia"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"k96","DOI":"10.1136\/bmj.k96","volume":"360","author":"K Adelborg","year":"2018","unstructured":"Adelborg K, Szepligeti SK, Holland-Bill L, Ehrenstein V, Horv\u00e1th-Puh\u00f3 E, Henderson VW et al (2018) Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ 360:k96","journal-title":"BMJ"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1212\/WNL.0b013e3181d0cc8b","volume":"74","author":"ME Bigal","year":"2010","unstructured":"Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M et al (2010) Migraine and cardiovascular disease: a population-based study. Neurology 74:628\u2013635","journal-title":"Neurology"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/bmj.38302.504063.8F","volume":"330","author":"M Etminan","year":"2005","unstructured":"Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63","journal-title":"BMJ"},{"issue":"6","key":"1044_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.55.6.754","volume":"55","author":"S. D. Silberstein","year":"2000","unstructured":"Silberstein SD (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754\u2013762","journal-title":"Neurology"},{"issue":"1","key":"1044_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/head.12499","volume":"55","author":"Michael J. Marmura","year":"2015","unstructured":"Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache 55:3\u201320","journal-title":"Headache: The Journal of Head and Face Pain"},{"key":"1044_CR16","volume-title":"FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes","author":"FDA","year":"2015","unstructured":"FDA. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes, 2015. \n                    https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm451800.htm\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR17","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Coxib and Traditional NSAID Trialists\u2019 (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N et al (2013) Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 382:769\u2013779","journal-title":"Lancet"},{"key":"1044_CR18","doi-asserted-by":"crossref","unstructured":"Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E et al (2017) Risk of acute myocardial infarction with NSAIDs in real world use: Bayesian meta-analysis of individual patient data. BMJ 357:j1909","DOI":"10.1136\/bmj.j1909"},{"key":"1044_CR19","unstructured":"Imitrex tablets prescribing information, 2012. GlaxoSmithKline Research Triangle Park, NC. \n                    http:\/\/us.gsk.com\/products\/assets\/us_imitrex_tablets.pdf\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR20","unstructured":"Amerge (naratriptan hydrochloride) tablets prescribing information, 2016. GlaxoSmithKline Research Triangle Park, NC. \n                    https:\/\/www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Amerge\/pdf\/AMERGE-PI-PIL.PDF\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR21","unstructured":"Maxalt (rizatriptan benzoate) prescribing information, 2013. Merck & Co. Whitehouse Station, NJ. \n                    https:\/\/www.merck.com\/product\/usa\/pi_circulars\/m\/maxalt\/maxalt_pi.pdf\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR22","unstructured":"Relpax (eletriptan hydrobromide) tablets prescribing information, 2008. Roerig division of Pfizer New York, NY. \n                    http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=986dc112-b97-44a3-bfaf-074f906f8bb2\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR23","unstructured":"Zomig (zolmitriptan) prescribing information, 2012. AstraZeneca\/Impax Pharmaceuticals Hayward, CA. \n                    http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=294d60f3-005b-40d9-a404-cdd77f62b820\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR24","unstructured":"Frova (frovatriptan succinate) prescribing information, 2007. Endo Pharmaceuticals, Inc. Chadds Ford, PA. \n                    http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=294d60f3-005b-40d9-a404-cdd77f62b820\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR25","unstructured":"Axert (almotriptan malate) tablets prescribing information, 2011; Janssen Pharmaceuticals, Inc. Titusville, NJ. \n                    http:\/\/dailymed.nlm.nih.gov\/dailymed\/lookup.cfm?setid=b13ba9bf-1661-456a-8eae-6d110ea08c94\n                    \n                  . Accessed 25 Apr 2019"},{"key":"1044_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/head.12962","volume":"57","author":"DC Buse","year":"2017","unstructured":"Buse DC, Reed ML, Fanning KM, Kurth T, Lipton RB (2017) Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 57:31\u201344","journal-title":"Headache"},{"key":"1044_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/brain\/awn321","volume":"132","author":"PJ Goadsby","year":"2009","unstructured":"Goadsby PJ (2009) The vascular theory of migraine--a great story wrecked by the facts. Brain 132:6\u20137","journal-title":"Brain"},{"key":"1044_CR28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.nurt.2010.03.003","volume":"7","author":"L Neeb","year":"2010","unstructured":"Neeb L, Meents J, Reuter U (2010) 5-HT (1F) receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 7:176\u2013182","journal-title":"Neurotherapeutics"},{"key":"1044_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1574884712666170419155048","volume":"12","author":"AS Xavier","year":"2017","unstructured":"Xavier AS, Lakshmanan M, Gunaseelan V (2017) The journey of the non-vascular relief for migraine: from \u2018triptans\u2019 to \u2018ditans\u2019. Curr Clin Pharmacol 12:36\u201340","journal-title":"Curr Clin Pharmacol"},{"key":"1044_CR30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/S0140-6736(01)06347-4","volume":"358","author":"DJ Goldstein","year":"2001","unstructured":"Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW et al (2001) Selective seratonin 1F (5-HT (1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 358:1230\u20131234","journal-title":"Lancet"},{"key":"1044_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-3-0348-8845-5_6","volume":"51","author":"KW Johnson","year":"1998","unstructured":"Johnson KW, Phebus LA, Cohen ML (1998) Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 51:219\u2013244","journal-title":"Prog Drug Res"},{"issue":"9","key":"1044_CR32","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1097\/00001756-199707070-00029","volume":"8","author":"Kirk W. Johnson","year":"1997","unstructured":"Johnson KW, Schaus JM, Durkin MM, Audia JE, Kaldor SW, Flaugh ME et al (1997) 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport 8:2237\u20132240","journal-title":"NeuroReport"},{"key":"1044_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1046\/j.1468-2982.2003.00525.x","volume":"23","author":"NM Ramadan","year":"2003","unstructured":"Ramadan NM, Skljarevski V, Phebus LA, Johnson KW (2003) 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia 23:776\u2013785","journal-title":"Cephalalgia"},{"key":"1044_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","volume":"15","author":"M Vila-Pueyo","year":"2018","unstructured":"Vila-Pueyo M (2018) Targeted 5-HT1F therapies for migraine. Neurotherapeutics 15:291\u2013303","journal-title":"Neurotherapeutics"},{"key":"1044_CR35","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO et al (2010) Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30:1159\u20131169","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"1044_CR36","first-page":"152","volume":"36","author":"M Vila-Pueyo","year":"2016","unstructured":"Vila-Pueyo M, Strother IC, Page K, Loaraine H, Kovalchin J, Goadsby PJ et al (2016) Lasmiditan inhibits trigeminovascular nociceptive transmission. Cephalalgia 36(Suppl 1):152\u2013153","journal-title":"Cephalalgia"},{"key":"1044_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0014-2999(99)00114-4","volume":"372","author":"T Nilsson","year":"1999","unstructured":"Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T et al (1999) Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur J Pharmacol 372:49\u201356","journal-title":"Eur J Pharmacol"},{"key":"1044_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.pharmthera.2018.01.005","volume":"186","author":"E Rubio-Beltran","year":"2018","unstructured":"Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, MaassenVanDenBrink A (2018) Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther 186:88\u201397","journal-title":"Pharmacol Ther"},{"key":"1044_CR39","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1046\/j.1365-2125.1999.00851.x","volume":"47","author":"Z Razzaque","year":"1999","unstructured":"Razzaque Z, Heald MA, Pickard JD, Maskell L, Beer MS, Hill RG et al (1999) Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol 47:75\u201382","journal-title":"Br J Clin Pharmacol"},{"key":"1044_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.bjp.0703081","volume":"129","author":"I Bouchelet","year":"2000","unstructured":"Bouchelet I, Case B, Olivier A, Hamel E (2000) No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501\u2013508","journal-title":"Br J Pharmacol"},{"issue":"1S","key":"1044_CR41","first-page":"104","volume":"36","author":"E Rubio-Beltr\u00e1n","year":"2016","unstructured":"Rubio-Beltr\u00e1n E, Haanes K, Labastida-Ram\u00edrez A, de Vries R, Danser J, Gralinski M et al (2016) Lasmiditan and sumatriptan: comparison of in vivo vascular constriction in the dog and in vitro contraction of human arteries. Cephalalgia 36(1S):104\u2013105","journal-title":"Cephalalgia"},{"issue":"1S","key":"1044_CR42","first-page":"363","volume":"37","author":"E Rubio-Beltr\u00e1n","year":"2017","unstructured":"Rubio-Beltr\u00e1n E, Labastida-Ram\u00edrez A, van den Bogaerdt A, Bogers A, Zanelli E, Meeus L et al (2017) In vitro characterization of agonist binding and functional activity at a panel of serotonin receptor subtypes for lasmiditan, triptans and other 5-HT receptor ligands and activity relationships for contraction of human isolated coronary artery. Cephalalgia 37(1S):363","journal-title":"Cephalalgia"},{"issue":"24","key":"1044_CR43","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB et al (2018) Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 91(24):e2222\u2013e2232","journal-title":"Neurology."},{"key":"1044_CR44","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK et al (2019) Phase 3 randomized, placebo-controlled, double blind study of lasmiditan for acute treatment of migraine. Brain 142:1894\u20131904","journal-title":"Brain"},{"issue":"25 suppl 2","key":"1044_CR45","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"David C. Goff","year":"2013","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al (2014) 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 129:S49\u2013S73","journal-title":"Circulation"},{"key":"1044_CR46","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486\u20132497","journal-title":"JAMA"},{"key":"1044_CR47","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C et al (2018) 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:e127\u2013e248"},{"key":"1044_CR48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1177\/2168479016628574","volume":"50","author":"B Crowe","year":"2016","unstructured":"Crowe B, Chuang-Stein C, Lettis S, Brueckner A (2016) Reporting adverse drug reactions in product labels. Ther Innov Regul Sci 50:455\u2013463","journal-title":"Ther Innov Regul Sci"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1044-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-019-1044-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-019-1044-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T23:19:01Z","timestamp":1598570341000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-019-1044-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,29]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1186\/s10194-019-1044-6","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,29]]},"assertion":[{"value":"30 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These studies were conducted in accordance with the principles of the Declaration of Helsinki. The institutional review board or independent ethics committee at each site approved the protocols, and all patients provided written informed consent. All authors had access to the study data and have reviewed and approved the final manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RES was a Lilly-paid consultant for galcanezumab clinical trials Data Monitoring Committee. HMH, EBD, RK, EGD, and PHB are all employees and shareholders of Eli Lilly and Company and\/or one of its subsidiaries. EGD was also an advisory board member for Eli Lilly prior to her employment and served on speakers\u2019 bureaus for Allergan Botox, Amgen, and Teva. AJS served as a consultant for Alder, eNeura, Amgen, Eli Lilly and Company, and Novartis. AJS also received grant funding from the Migraine Research Foundation - Mayo Clinic Intramural funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}